Palisade Bio presents preclinical data on PALI-2108

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients with ulcerative colitis. The presented data highlighted the efficacy and safety profile of PALI-2108 in a mouse model of colitis, with a particular focus on its impact on PDE4B expression, cAMP levels, and TNF-alpha suppression as well as predicting efficacious PALI-0008 levels in patients. Key Highlights: PALI-2108 treatment significantly improved clinical parameters of colitis, including the DAI, body weight, and colon length in a dose-dependent manner. PALI-2108 administration resulted in a marked dose-dependent reduction of PDE4B expression in colon tissues, with higher cAMP levels and a notable suppression of TNF-alpha compared to standard treatments like cyclosporine A and apremilast. By increasing cAMP levels and modulating key inflammatory mediators such as TNF-alpha, PALI-2108 shows significant potential for reducing symptoms associated with UC. The preclinical data underscore PALI-2108’s efficacy and safety profile, with minimal CNS toxicity and favorable dose-dependent effects.